CY1108165T1 - ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ - Google Patents

ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ

Info

Publication number
CY1108165T1
CY1108165T1 CY20081100682T CY081100682T CY1108165T1 CY 1108165 T1 CY1108165 T1 CY 1108165T1 CY 20081100682 T CY20081100682 T CY 20081100682T CY 081100682 T CY081100682 T CY 081100682T CY 1108165 T1 CY1108165 T1 CY 1108165T1
Authority
CY
Cyprus
Prior art keywords
decoy
treatment
stat
skin
atophic
Prior art date
Application number
CY20081100682T
Other languages
English (en)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg, Inc. filed Critical Anges Mg, Inc.
Publication of CY1108165T1 publication Critical patent/CY1108165T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Μία φαρμακευτική σύνθεση για την διεξαγωγή θεραπευτικής αγωγής έναντι δερματοπαθειών, όπου η φαρμακευτική σύνθεση περιλαμβάνει τουλάχιστον ένα δόλωμα και έναν φαρμακευτικά παραδεκτό φορέα. Το τουλάχιστον ένα δόλωμα μπορεί να επιλεγεί από την ομάδα που αποτελείται από ένα δόλωμα NF-κΒ, ένα δόλωμα STAT-1, ένα δόλωμα GATA-3, ένα δόλωμα STAT-6, ένα δόλωμα ΑΡ-1 και ένα δόλωμα Ets. Το τουλάχιστον ένα δόλωμα μπορεί να είναι ένα ολιγονουκλεοτίδιο που περιλαμβάνει τουλάχιστον δύο δολώματα συνδεδεμένα προς αλλήλους, ενώ τα τουλάχιστον δύο δολώματα επιλέγονται από την ομάδα που αποτελείται από ένα δόλωμα NF-κΒ, ένα δόλωμα STAT-1, ένα δόλωμα GATA-3, ένα δόλωμα STAT-6, ένα δόλωμα ΑΡ-1 και ένα δόλωμα Ets. Η δερματοπάθεια μπορεί να είναι η ατοπική δερματίτιδα, κοινή ψωρίαση, δερματίτιδα εξ επαφής, χηλοειδής ακμή (kelcid), έλκωση λόγω κατάκλισης, ελκώδης κολίτιδα ή η ασθένεια του Crohn.
CY20081100682T 2001-02-20 2008-06-30 ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ CY1108165T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20
EP02711351A EP1362600B1 (en) 2001-02-20 2002-02-06 TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS

Publications (1)

Publication Number Publication Date
CY1108165T1 true CY1108165T1 (el) 2014-02-12

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100682T CY1108165T1 (el) 2001-02-20 2008-06-30 ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ

Country Status (11)

Country Link
US (2) US9012417B2 (el)
EP (2) EP1362600B1 (el)
JP (2) JP3778357B2 (el)
AT (1) ATE390938T1 (el)
CY (1) CY1108165T1 (el)
DE (1) DE60225899T2 (el)
DK (1) DK1362600T3 (el)
ES (1) ES2307733T3 (el)
PT (1) PT1362600E (el)
TW (1) TWI308492B (el)
WO (1) WO2002066070A1 (el)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011687A1 (en) * 1993-10-29 1995-05-04 Dzau Victor J Therapeutic use of cis-element decoys in vivo
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
DE10148886A1 (de) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition von STAT-1
CN1784248B (zh) * 2003-05-09 2010-11-10 森下龙一 收容药剂的无针注射器
WO2005004913A1 (ja) * 2003-07-09 2005-01-20 Anges Mg, Inc. デコイを含む薬学的組成物およびその使用方法
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
EP1691817A2 (en) * 2003-12-02 2006-08-23 Corgentech, Inc. NF-kB OLIGONUCLEOTIDE DECOY MOLECULES
WO2005062854A2 (en) * 2003-12-19 2005-07-14 University Of Cincinnati Polyamides for nucleic acid delivery
JP2008513513A (ja) * 2004-09-21 2008-05-01 アネシヴァ， インコーポレイテッド ポリヌクレオチドの送達
EP1803811B1 (en) 2004-10-22 2011-05-11 AnGes MG, Inc. Chimeric (double) decoy
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
EP1892293A4 (en) 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
US20100035793A1 (en) * 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20090227661A1 (en) * 2005-12-22 2009-09-10 Zhiguo Wang Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JPWO2007072909A1 (ja) 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
WO2008099906A1 (ja) 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
ES2619314T3 (es) 2007-05-11 2017-06-26 Adynxx, Inc. Expresión génica y dolor
WO2009119836A1 (ja) * 2008-03-28 2009-10-01 アンジェスＭｇ株式会社 転写因子デコイを有効成分とする外用剤組成物
JP6251247B2 (ja) 2012-05-10 2017-12-20 エーダイニクス インコーポレイテッド 活性成分の送達のための製剤
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
WO1995011687A1 (en) * 1993-10-29 1995-05-04 Dzau Victor J Therapeutic use of cis-element decoys in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
KR100192149B1 (ko) * 1994-10-24 1999-06-15 이시노 요시푸사 경피 투여형 제제
ES2285712T3 (es) * 1995-05-12 2007-11-16 Anges Mg, Inc. Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
KR19990071523A (ko) * 1995-11-21 1999-09-27 해리 에이. 루스제 Il－8 및 il－8 수용체에 대한 안티센스올리고누클레오티드에 의한 종양 성장의 억제방법
JP2002510319A (ja) * 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
JP2001055331A (ja) 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
DE60131498T8 (de) * 2000-02-02 2009-01-29 Anges Mg Inc., Toyonaka VIRUSHÜLLENVEKTOR FüR DIE GENÜBERTRAGUNG
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
PT1362600E (pt) 2001-02-20 2008-07-09 Anges Mg Inc Utilização tópica de iscos de nf-kb para o tratamento da dermatite atópica
ATE421889T1 (de) * 2002-02-01 2009-02-15 Anges Mg Inc Decoy-enthaltende pharmazeutische zusammensetzungen zur behandlung von aneurysmen
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Also Published As

Publication number Publication date
EP1690544B1 (en) 2017-09-13
DE60225899D1 (de) 2008-05-15
ES2307733T3 (es) 2008-12-01
EP1362600B1 (en) 2008-04-02
EP1690544A3 (en) 2012-03-07
DE60225899T2 (de) 2009-04-09
JPWO2002066070A1 (ja) 2004-06-17
TWI308492B (el) 2009-04-11
JP3778357B2 (ja) 2006-05-24
US20040162251A1 (en) 2004-08-19
PT1362600E (pt) 2008-07-09
EP1362600A1 (en) 2003-11-19
EP1690544A2 (en) 2006-08-16
DK1362600T3 (da) 2008-07-28
JP4987022B2 (ja) 2012-07-25
US9012417B2 (en) 2015-04-21
WO2002066070A1 (fr) 2002-08-29
JP2009102428A (ja) 2009-05-14
ATE390938T1 (de) 2008-04-15
EP1362600A4 (en) 2005-09-21
US20090105183A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
CY1108165T1 (el) ΤΟΠΙΚΗ ΧΡΗΣΗ ΔΟΛΩΜΑΤΟΣ NF-κΒ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΤΗΣ ΑΤΟΠΙΚΗΣ ΔΕΡΜΑΤΙΤΙΔΑΣ
WO2002043652A3 (en) Anti-proliferative drugs
WO2001048190A8 (en) Therapeutic uses of lna-modified oligonucleotides
ES2191192T3 (es) Tienopirimidinas.
CY1107467T1 (el) Χρηση οξεογονων υδρογονοτροφων στελεχων για την προληψη ή την αγωγη πεπτικων διαταραχων
CY1105070T1 (el) Μεθοδος και συνθεσεις που χρησιμοποιουν κιναζολινονες
DE60124285D1 (de) Beschichtete medizinische geräte
EP1181947A3 (en) Spinal cord stimulation leads
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
ES2192839T3 (es) Timosina beta 4 oxidada.
ITMI20041550A1 (it) Uso di batteri probiotici per la preparazione di composizioni topiche per la protezione dell'epidermide
CO5160266A1 (es) Nuevos agentes antibacterianos de isoxazolinona
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
MY138883A (en) Use of asiatic acid for treatment of cencer
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
ES2187646T3 (es) Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes.
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
BR0115882A (pt) Emprego de compostos de 1-fenil-3-dimetilaminopropano no tratamento da incontinência urinária
AR002272A1 (es) Uso de amidas de fenilciclohexilcarboxilicos
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
WO2005056520A8 (en) Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy